Protein Supplementation and Fat Mass Loss
Effects of Protein Supplementation on Fat Mass Loss in Free Living Individuals With Overweight and Obesity - A Randomized Controlled Trial
1 other identifier
interventional
60
1 country
1
Brief Summary
Investigators examined the associations between whey protein supplementation before meals with energy balance and body composition.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable obesity
Started Oct 2018
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 18, 2018
CompletedFirst Posted
Study publicly available on registry
September 20, 2018
CompletedStudy Start
First participant enrolled
October 1, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 28, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
February 28, 2020
CompletedNovember 26, 2019
November 1, 2019
1.4 years
September 18, 2018
November 22, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Group differences in change in body fat mass
Fat mass will be measured using a Lunar Dual X-Ray Absorptiometry Scanner (GE Medical Systems) and the Imp SFB7 BIS (ImpediMed Ltd, Australia) at baseline, and at end of the treatment period. The outcome to be compared between groups will be change in percent fat mass from baseline to post treatment.
Baseline, end of 6th week and end of 12th week of intervention period
Secondary Outcomes (6)
Group differences in change in physical activity energy expenditure
Baseline and week 7 of the intervention period
Group differences in changes in meal satiety and hunger
Baseline, day 14, 43 and 83 of intervention period
Group differences in change in resting Metabolic Rate
Baseline, and at end 12 weeks of intervention period
Group differences in changes in food intake
Baseline, at week 7, and at week 12 of intervention period
Group differences in changes in grip strength
Baseline and after the 6th and 12th week of intervention.
- +1 more secondary outcomes
Study Arms (2)
Protein group
EXPERIMENTALThe protein group will consume 30g of 100% whey protein shake 1 hour before lunch and before dinner, for 12 weeks
Control group
NO INTERVENTIONControl group will not consume any protein supplements. They will continue the usual feeding habits
Interventions
Participants in the protein group will be provided 100% whey protein powder and will be advised to drink 30g of protein dissolved in 237ml (8oz) of water, one hour before lunch and dinner.
Eligibility Criteria
You may qualify if:
- Ages 19-55 years
- Body mass index more than or equal to 23 kg/m2 for Asians and more than or equal to 25 kg/m2 for other ethnic groups up to 40 kg/m2
- Individuals who are able to speak, read and write in English
You may not qualify if:
- Lactose intolerance
- Food allergies to milk products
- Religious affiliations that include specific food guidelines.
- Participation in any weight-reduction program, weight-loss diet, or other special diet within the previous 3 months or planning to enroll in those within next 3 months
- History of prior surgical procedure for weight control or planning to have one within next 3 months
- Weight loss or gain of \>5% of body weight in the past 6 months for any reason except post-partum weight loss.
- Current smoker or quit smoking less than 6 months prior.
- Any major disease, including:
- Active cancer or cancer requiring treatment in the past 2 years (except nonmelanoma skin cancer).
- Active or chronic infections, including self-reported HIV positivity and active tuberculosis.
- Active cardiovascular disease or event including hospitalization or therapeutic procedures for treatment of heart disease (e.g., coronary artery bypass, percutaneous transluminal coronary angioplasty) in the past 6 months; New York Heart Association Functional Class \>2 with respect to congestive heart failure; stroke or transient ischemic attack in the past 6 months.
- Gastrointestinal disease, including self-reported chronic hepatitis or cirrhosis, any episode of alcoholic hepatitis or alcoholic pancreatitis within past year, inflammatory bowel disease requiring treatment in the past year, recent or significant abdominal surgery (e.g., gastrectomy).
- Active renal disease.
- Lung disease: chronic obstructive airway disease requiring use of oxygen.
- Diagnosed diabetes (type 1 or 2).
- +17 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Texas Tech University
Lubbock, Texas, 79409, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Emily J (806)834-6556
Texas Tech University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
September 18, 2018
First Posted
September 20, 2018
Study Start
October 1, 2018
Primary Completion
February 28, 2020
Study Completion
February 28, 2020
Last Updated
November 26, 2019
Record last verified: 2019-11
Data Sharing
- IPD Sharing
- Will not share